This week, we were able to estimate vaccine effectiveness (VE) against hospitalisation for the first time. In short, good news. VE after a booster is close to 90%. The full update from our team is published in this week's technical briefing update:…

As before, we first used a test-negative case control study design to estimate VE against symptomatic disease. This analysis included tests between 27th November and 24th December, and included 169,888 Delta cases and 204,036 Omicron cases.

Amongst those who received two doses of AZ (ChAdOx1-3), VE against symptomatic disease dropped to ~40% 10 weeks after a Pfizer (BNT162b2) booster and ~60% 5-9 weeks after a Moderna (mRNA-1273) booster.

Amongst those who received two doses of Pfizer (BNT162b2), VE against symptomatic disease dropped to ~50% 10 weeks after a Pfizer (BNT162b2) booster and ~70% 5-9 weeks after a Moderna (mRNA-1273) booster.

To investigate VE against hospitalisation, symptomatic cases were first linked to the Emergency Care Dataset to identify admissions 0 to 14 days after the positive test. Cox survival analysis was then used to estimate the risk of hospital admission by vaccination status.

The odds ratios for symptomatic disease were multiplied by the hazard ratios (HR) for hospitalisation among symptomatic cases in order to estimate VE against hospitalisation.

For symptomatic cases, 3 doses of vaccine (any manufacturer) was associated with a 68% reduced risk of hospitalisation. When combined with VE against symptomatic disease, this was equivalent to a VE against hospitalisation of 88% 2+ weeks after a booster dose.

We hope to soon be able to estimate VE against hospitalisation using the test-negative case control design. We did not yet have enough data to stratify VE against hospitalisation by vaccine brand, but will also be looking at this as soon as possible.

Further data is also needed to investigate the duration of protection against severe disease with Omicron conferred by the vaccines. However, experience with previous variants suggests this will be longer than protection against symptomatic disease.

The report also contains updates on what we know so far about Omicron severity - see below from @kallmemeg for an explainer


• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Freja Kirsebom

Freja Kirsebom Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @freja_kirsebom

23 Dec 21
An update from our team on the latest vaccine effectiveness (VE) estimates against symptomatic infection with the Omicron variant has now been published in the UKHSA Variant Technical Briefing 33 (page 24).…

With more data available, we now have better estimates of VE following a booster (Pfizer or Moderna) after either an AZ or Pfizer primary course. We still did not have enough data to estimate VE against hospitalisation but we will be looking at this as as soon as possible.

As last time, we used a test-negative case control study design to estimate VE against symptomatic COVID-19 disease. This analysis included Pillar 2 testing data from 27th November to 17th December. Here, we had data from 68,489 Omicron cases and 147,597 Delta cases.

Read 9 tweets
10 Dec 21
Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses.

More below 👇

We used a test negative case control design to estimate VE against symptomatic COVID-19 with the Omicron variant compared to Delta. The odds of vaccination in PCR positive cases was compared to the odds of vaccination in those who test negative.

Pillar 2 tests were classified as either Delta or Omicron from the period 27/11 – 6/12 based on sequencing and SGFT where sequencing wasn’t available. From 27/11, at least 80% of PCR tests which included the S-gene as a target and which had SGTF were the Omicron variant.

Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!